Abstract
Background Building on evidence linking urinary glyphosate to chronic liver disease (CLD) and hepatocellular carcinoma (HCC), we developed urinary pesticide profiling integrated with machine learning risk prediction (MLRP) to stratify risk in high-exposure populations.
Methods We conducted a case–control study within the Thailand Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC; 2011–2016; n=593): 228 CLD, 116 HCC, and 249 controls. Eight urinary pesticides were quantified by LC–MS/MS (pendimethalin, oxadiazon, metsulfuron-methyl, butachlor, 2,4-dichlorophenoxyacetic acid [2,4-D], cypermethrin, flocoumafen, bromadiolone). A composite Pesticide Load Score (PLS), with and without glyphosate, estimated burden. Two predictive models were developed: a logistic-regression Pesticide-Informed Liver Cancer Risk Score (PILCRS) and an Extreme Gradient Boosting (XGBoost) classifier that incorporated age, sex, alcohol use, occupation, and PLS. Internal validity used 1,000 bootstrap resamples with optimism-corrected calibration.
Findings Predicted CLD probability increased from 30% in the lowest PLS quartile to over 70% in the highest, and HCC from 10% to 40% (p<0ꞏ0001). Relative estimates were consistent; the highest versus lowest quartile yielded odds ratios of 2ꞏ84 (95% CI 1ꞏ66–4ꞏ91) for CLD and 4ꞏ76 (2ꞏ30– 10ꞏ29) for HCC. Cypermethrin remained independently associated. After optimism correction, both models demonstrated strong discrimination and calibration.
Interpretation This framework establishes a scalable, exposure-informed tool for liver disease prediction. Findings underscore pesticide burden as a modifiable risk factor and align with Sustainable Development Goal 3ꞏ9 and WHO–FAO priorities in low- and middle-income countries (LMICs). External validation is essential.
Funding National Institutes of Health (USA); Thailand Science Research and Innovation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, U.S. National Institutes of Health (ZIA BC 011492). Work in Thailand was supported by the Chulabhorn Research Institute, Bangkok, Thailand, and in part by Thailand Science Research and Innovation (TSRI) through the Chulabhorn Research Institute (grant 49890/4759784). No authors or their institutions received any payments or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the Chulabhorn Research Institute (Bangkok, Thailand) and the Institutional Review Board of the U.S. National Cancer Institute (Bethesda, MD, USA) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available from the corresponding author upon reasonable request.
